Roth Capital Has Negative Outlook of CVE:HIV FY2025 Earnings

HIVE Blockchain Technologies Ltd. (CVE:HIV) – Investment analysts at Roth Capital lowered their FY2025 earnings per share estimates for shares of HIVE Blockchain Technologies in a research report issued on Thursday, January 30th. Roth Capital analyst D. Aftahi now expects that the company will earn ($0.53) per share for the year, down from their previous estimate of ($0.52). Roth Capital has a “Strong-Buy” rating on the stock. Roth Capital also issued estimates for HIVE Blockchain Technologies’ Q1 2026 earnings at ($0.10) EPS, Q2 2026 earnings at $0.01 EPS, Q3 2026 earnings at ($0.03) EPS, Q4 2026 earnings at $0.19 EPS, FY2026 earnings at $0.10 EPS, FY2027 earnings at $0.62 EPS and FY2028 earnings at $0.06 EPS.

Several other equities research analysts have also weighed in on HIV. Cantor Fitzgerald raised HIVE Blockchain Technologies to a “strong-buy” rating in a research report on Tuesday, October 29th. Keefe, Bruyette & Woods raised shares of HIVE Blockchain Technologies to a “moderate buy” rating in a report on Wednesday, January 8th. Four investment analysts have rated the stock with a strong buy rating, According to data from MarketBeat, the stock presently has an average rating of “Strong Buy”.

HIVE Blockchain Technologies Stock Performance

HIVE Blockchain Technologies (CVE:HIV) last released its earnings results on Tuesday, November 12th. The company reported C($0.08) earnings per share for the quarter, topping analysts’ consensus estimates of C($0.12) by C$0.04. During the same quarter in the previous year, the business earned ($0.39) EPS.

HIVE Blockchain Technologies Ltd. is a services company in the Business Services industry.